Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: modified chlorotoxin radiotherapeutics - TransMolecular

Drug Profile

Research programme: modified chlorotoxin radiotherapeutics - TransMolecular

Alternative Names: 123I-TM-601; TM-601-I-123; TM-901; TM-902

Latest Information Update: 07 Jan 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TransMolecular
  • Developer Blaze Bioscience; TransMolecular
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Diagnostic imaging enhancers; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer
  • Discontinued Solid tumours

Most Recent Events

  • 09 Nov 2015 Chlorotoxin-based infrared imaging agent licensed to Blaze Bioscences
  • 09 Nov 2015 Early research in Cancer (Diagnosis) in USA (unspecified route)
  • 22 Aug 2003 TransMolecular is seeking partnership opportunities for this programme in Solid tumours (http://www.transmolecular.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top